OMass gives its congenital adrenal hyperplasia program a major financing lift
OMass Therapeutics has raised $310 million in Series C financing to advance a pipeline anchored by OMS1620, a small molecule aimed at a rare endocrine disease with few therapeutic options. The timing matters because congenital adrenal hyperplasia remains a disorder in which treatment often substitutes one hormonal problem for another: the disease itself creates adrenal hormone imbalance, while the standard therapy can produce substantial glucocorticoid toxicity when pushed to the doses needed for control.
Congenital adrenal hyperplasia is an inherited condition in which the adrenal glands lack an enzyme required to make key hormones. The resulting cascade can drive low sodium levels, dehydration, and adrenal crisis, a potentially life-threatening emergency tied to deficient cortisol production. In day-to-day endocrine care, the clinical burden is not only biochemical; it is also the lifelong requirement to balance hormone replacement against the consequences of chronic steroid exposure.
Why an MC2 receptor blocker could change the treatment equation
OMass is pursuing a different lever in the pathway. OMS1620 is designed to block the melanocortin-2, or MC2, receptor in the adrenal glands, a receptor involved in the signaling that drives cortisol production. By interrupting that signal, the drug is intended to reduce the hormone excess that contributes to the abnormal endocrine state in CAH while allowing more patients to approach hormone levels closer to normal even as they remain on glucocorticoids.
The company describes OMS1620 as a molecule built to stay bound to its target receptor longer and to maintain activity in the face of rising hormone levels that normally stimulate adrenal cortisol production. In mechanistic terms, that durability could matter because endocrine signaling is dynamic, not static; a drug that can hold its target during fluctuating physiologic pressure may have a better chance of smoothing the hormonal swings that complicate CAH management. One sentence captures the clinical logic plainly: the goal is not just suppression, but stable suppression.
The lead program is also headed toward a broader endocrine role. OMass plans to take OMS1620 through Phase 2 testing in both CAH and ACTH-dependent Cushing’s syndrome, another disorder in which adrenal hormone excess drives major morbidity. The financing will also support earlier-stage assets, giving the company room to continue work beyond a single development track.
Crenessity sets the commercial benchmark in CAH
The market OMass is entering already has a standard bearer. Crenessity, a Neurocrine Biosciences product approved by the FDA in 2024, is the only drug currently available for CAH. It is an oral small molecule designed to block CRFR1, reducing pituitary secretion of adrenocorticotropic hormone, or ACTH, and thereby lowering the production of downstream hormones that contribute to hormonal imbalance in CAH.
Neurocrine reported $301.2 million in Crenessity sales for 2025, a figure that shows both the commercial demand and the unmet need in this rare disease space. Even so, a single approved therapy leaves room for alternatives, especially if a new candidate can address hormone control through a distinct mechanism, improve tolerability, or complement existing glucocorticoid treatment in a way that reduces steroid burden. In rare endocrine disease, mechanism is more than a research detail; it is often the basis for whether a treatment can carve out a role in practice.
Competition may intensify further. Vertex Pharmaceuticals is also pursuing the CAH market with atumelnant, a small molecule inhibitor of ACTH that came from its recently closed $10 billion acquisition of Crinetics Pharmaceuticals. The field is no longer a one-company race, and that raises the bar for differentiation on efficacy, safety, and the practical burden placed on patients who already face a lifelong endocrine disorder.
New capital reaches beyond one endocrine asset
The Series C round, announced Oct. 15, was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences also participated, along with earlier backers Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford.
The financing is not being directed solely at endocrine medicine. OMass is also advancing an earlier-stage SLC15A4 inhibitor that the company describes as a potential first-in-class treatment for lupus and other diseases tied to interferon overproduction and pathogenic B-cell activation. That breadth suggests a platform strategy rather than a one-drug bet, with the company using the new capital to support both near-term clinical progression and longer-term discovery work.
A substantial raise can reshape a development timeline, but it does not substitute for human data. Phase 2 testing will have to show whether the receptor-blocking strategy translates into meaningful hormonal control in CAH and whether the same biology can be leveraged in ACTH-dependent Cushing’s syndrome. The critical questions are clinical ones: how well the drug controls disease activity, how it compares with existing treatment, and whether its receptor-binding properties deliver a practical advantage in patients whose endocrine systems are already under constant stress.
The next proof point is clinical, not financial
OMass now has the capital to push OMS1620 into the studies that will determine whether the program can compete in a field already anchored by an approved therapy and a high-profile challenger. For patients with CAH, the stakes are immediate and concrete: better hormonal control, less reliance on high-dose glucocorticoids, and fewer complications from long-term steroid exposure.
The financing gives the company time. Phase 2 data will decide whether the biology earns a place in routine endocrine care.